Developer docs
API playgroundTry for free, no card

Search company profiles

Valitacell

Full company profile

uuid0005nrt

Namestring
Valitacell
Legal namestring
ValitaCell Ltd
Websiteurl
valitacell.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

ValitaCell Ltd is a Dublin-based biotechnology company founded in 2014 that develops plate-based fluorescence polarization assays for rapid quantification of IgG antibodies directly from cell culture samples. Its core product line, branded Valita Titer, comprises 96-well and 384-well assays covering two IgG concentration ranges (2.5-100 mg/L and 100-2000 mg/L), engineered to deliver titer results in under 15 minutes without sample preparation, wash steps, or additional reagents. A companion line, Valita Aggregation Pure, addresses protein aggregation measurement, and the two product families are positioned to be bundled with Agilent BioTek multimode microplate readers for an integrated titer-plus-aggregation workflow. All products are labeled "For Research Use Only."

The company's commercial model is built on consumable kit sales with publicly listed unit pricing ($6,782 to $27,128 per kit) and quote-based pricing for the high-titer 384-well SKU. ValitaCell operates as a wholly-owned subsidiary of Beckman Coulter Life Sciences — itself a Danaher Corporation company — and sells exclusively through Beckman Coulter's global direct-sales force, e-commerce storefront, and inside-sales quote channel. The end customer base spans biopharmaceutical companies developing monoclonal antibody therapeutics, process development laboratories optimizing bioprocesses, and analytical development teams performing titer verification during biologics drug development. Headcount is reported at 1-10 employees, and the company functions primarily as a focused product-line entity within Danaher's life sciences portfolio rather than as an independent scaling startup.

Operationally, ValitaCell's differentiation centers on workflow compression (15-minute results vs. hours for ELISA/HPLC), precision (<2.5% RSD) and accuracy (>95%) specifications, and demonstrated automation compatibility on Beckman Biomek liquid handling workstations. The combined footprint of Beckman Coulter distribution and Danaher-level corporate backing positions Valita Titer as a branded reagent line rather than a venture-backed growth equity story.

Short descriptiontext

ValitaCell is a Dublin-based biotechnology company that develops fluorescence polarization-based IgG quantification assays (Valita Titer) for rapid biologics drug development, sold exclusively through parent Beckman Coulter Life Sciences.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
biologics analytics reagents, IgG quantification assays, fluorescence polarization assays, monoclonal antibody screening, protein aggregation testing
Industry4 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAB
Immunoassay Diagnostics (ELISA, chemiluminescence, serology)
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Biologics Analytics Reagents
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Assay Kit Sales
TypeOne Time License
Description

Sale of Valita Titer IgG quantification assay kits in 96-well and 384-well plate formats. Products include VAL003 (2.5-100 mg/L, 96-well at $6,782), VAL004 (100-2000 mg/L, 96-well at $8,975), VAL013 (2.5-100 mg/L, 384-well at $27,128), and VAL014 (100-2000 mg/L, 384-well).

beckman.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain
Pricing details4 tiers
1Valita Titer IgG Quantification Assay 96-well (2.5 - 100 mg/L) - VAL003
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$6,782.00 per kit

beckman.com
2Valita Titer IgG Quantification Assay 96-well (100 - 2000 mg/L) - VAL004
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$8,975.00 per kit

beckman.com
3Valita Titer IgG Quantification Assay 384-well (2.5 - 100 mg/L) - VAL013
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$27,128.00 per kit

beckman.com
4Valita Titer IgG Quantification Assay 384-well (100 - 2000 mg/L) - VAL014
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Quote-based pricing

beckman.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Valita Titer
Description

Plate-based, 96- and 384-well assays for rapid, cost-effective IgG quantification using fluorescence polarization technology. Valita Titer is among the industry's fastest IgG tests.

beckman.com
+1 more record
Core offering1 text field

ValitaCell develops and sells plate-based fluorescence polarization assay kits that quantify IgG antibodies directly from cell suspension without sample preparation, delivering results in under 15 minutes for biopharmaceutical clone screening, cell line development, and process optimization workflows. Its portfolio includes Valita Titer assays in 96-well and 384-well formats across low and high IgG concentration ranges, plus Valita Aggregation Pure kits for protein aggregation measurement, distributed exclusively through Beckman Coulter Life Sciences.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Results in less than 15 minutes (vs hours for ELISA/HPLC)
+4 more records
Product overview1 text field

ValitaCell (a Beckman Coulter company) offers a portfolio of plate-based fluorescence polarization assays for rapid IgG quantification in biologics drug discovery and development. The core product line consists of Valita Titer Assays available in 96-well and 384-well formats, each offered in two IgG concentration ranges (2.5-100 mg/L and 100-2000 mg/L). These assays measure IgG directly in cell suspension without sample preparation, providing results in under 15 minutes. Valita Aggregation Pure Assay Kits complement the titer assays for protein aggregation measurement. The complete solution can be bundled with Agilent BioTek multimode microplate readers for integrated protein titer and aggregation measurement workflows.

Product and service5 records
1Valita Titer IgG Quantification Assay 96-well (2.5 - 100 mg/L)
CategoryIgG quantification assay kit
Description

Plate-based 96-well fluorescence polarization assay for rapid IgG quantification directly from cell suspension, covering the 2.5-100 mg/L concentration range, with results in under 15 minutes; targeted at biopharmaceutical clone screening and cell line development workflows.

2Valita Titer IgG Quantification Assay 96-well (100 - 2000 mg/L)
CategoryIgG quantification assay kit
Description

Plate-based 96-well fluorescence polarization assay for rapid IgG quantification directly from cell suspension, covering the 100-2000 mg/L high-titer concentration range, with results in under 15 minutes; intended for high-titer bioprocess samples.

3Valita Titer IgG Quantification Assay 384-well (2.5 - 100 mg/L)
CategoryIgG quantification assay kit
Description

High-throughput 384-well fluorescence polarization assay for rapid IgG quantification, covering the 2.5-100 mg/L concentration range, enabling increased throughput for clone screening during drug discovery and development.

4Valita Titer IgG Quantification Assay 384-well (100 - 2000 mg/L)
CategoryIgG quantification assay kit
Description

High-throughput 384-well fluorescence polarization assay for rapid IgG quantification, covering the 100-2000 mg/L high-titer concentration range, designed for high-titer samples in scaled-up clone screening workflows.

5Valita Aggregation Pure Assay Kits
CategoryProtein aggregation assay kit
Description

Companion assay kits for protein aggregation measurement that, when bundled with Valita Titer assays and Agilent BioTek multimode microplate readers, enable a complete sub-15-minute protein titer and aggregation measurement workflow for biologics analytics.

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Beckman Coulter Life Sciences serves as the exclusive global distributor for ValitaCell products including Valita Titer IgG quantification assays and Valita Aggregation Pure assay kits. The products are integrated into Beckman Coulter's reagent portfolio and sold through their global sales network, e-commerce platform, and distribution channels. ValitaCell is identified as a Beckman Coulter Company, indicating a close distribution and ownership relationship.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bio-Rad offers Bio-Plex and ProA-based assays for IgG quantification in biologics workflows. As a broad incumbent in life science research, it competes with ValitaCell in clone screening and titer measurement within the same biopharma customer base.

TypeDirect peer
Description

Repligen sells the CTG (Cell Titer-Glo) and Protein A titer measurement systems used in bioprocess development. It directly competes with Valita Titer for rapid IgG quantification in cell line development, and is a similarly specialized life science tools provider for biologics.

TypeDirect peer
Description

ForteBio (now part of Sartorius) markets Octet BLI-based biosensors for rapid, label-free protein quantification including IgG titer. It targets the same clone screening and bioprocess development use cases as ValitaCell and is the most cited direct competitor on speed/throughput.

TypeBroad incumbent
Description

Cytiva supplies Protein A affinity columns and related titer measurement workflows for mAb manufacturing. It operates as a broad bioprocess incumbent whose analytics and consumables overlap with ValitaCell's cell line development focus.

TypeDirect peer
Description

Pall offers the Octet and other BLI-based systems (alongside other analytics) for rapid protein titer measurement; it is also a Danaher company, making it a direct intra-portfolio peer to ValitaCell with overlapping mAb workflow offerings.

TypeBroad incumbent
Description

Thermo Fisher offers ELISA kits, Protein A binding assays, and automated platforms for IgG titer across its life sciences portfolio. As a broad incumbent, it competes for the same biopharma analytics budgets ValitaCell targets via Beckman Coulter.

TypeEmerging player
Description

Agilent's BioTek line of multimode microplate readers is the instrument layer paired with Valita Titer assays. Agilent is adjacent/partnering rather than directly competing, but its instrumentation underpins the throughput positioning of ValitaCell's 384-well assays.

8Merck KGaA / MilliporeSigma
TypeBroad incumbent
Description

MilliporeSigma supplies ELISA-based titer assays and Prozain A / Protein A affinity products for clone screening in mAb development. As a broad life science tools incumbent, it competes for the same IgG quantification dollars.

TypeEmerging player
Description

PerkinElmer offers AlphaLISA and other homogeneous immunoassays for rapid IgG quantification in high-throughput formats. It overlaps with ValitaCell's plate-based, no-wash assay approach and is positioned as a competing rapid titer solution.

TypeOthers
Description

Providers of clone screening workstations and analytics for cell line development that integrate with rapid IgG titer assays. Included as ecosystem participants adjacent to ValitaCell's core assay workflow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valitacell

Biologics Analytics Reagentsvalitacell.com

ValitaCell is a Dublin-based biotechnology company that develops fluorescence polarization-based IgG quantification assays (Valita Titer) for rapid biologics drug development, sold exclusively through parent Beckman Coulter Life Sciences.

What Valitacell does

ValitaCell Ltd is a Dublin-based biotechnology company founded in 2014 that develops plate-based fluorescence polarization assays for rapid quantification of IgG antibodies directly from cell culture samples. Its core product line, branded Valita Titer, comprises 96-well and 384-well assays covering two IgG concentration ranges (2.5-100 mg/L and 100-2000 mg/L), engineered to deliver titer results in under 15 minutes without sample preparation, wash steps, or additional reagents. A companion line, Valita Aggregation Pure, addresses protein aggregation measurement, and the two product families are positioned to be bundled with Agilent BioTek multimode microplate readers for an integrated titer-plus-aggregation workflow. All products are labeled "For Research Use Only."

The company's commercial model is built on consumable kit sales with publicly listed unit pricing ($6,782 to $27,128 per kit) and quote-based pricing for the high-titer 384-well SKU. ValitaCell operates as a wholly-owned subsidiary of Beckman Coulter Life Sciences — itself a Danaher Corporation company — and sells exclusively through Beckman Coulter's global direct-sales force, e-commerce storefront, and inside-sales quote channel. The end customer base spans biopharmaceutical companies developing monoclonal antibody therapeutics, process development laboratories optimizing bioprocesses, and analytical development teams performing titer verification during biologics drug development. Headcount is reported at 1-10 employees, and the company functions primarily as a focused product-line entity within Danaher's life sciences portfolio rather than as an independent scaling startup.

Operationally, ValitaCell's differentiation centers on workflow compression (15-minute results vs. hours for ELISA/HPLC), precision (<2.5% RSD) and accuracy (>95%) specifications, and demonstrated automation compatibility on Beckman Biomek liquid handling workstations. The combined footprint of Beckman Coulter distribution and Danaher-level corporate backing positions Valita Titer as a branded reagent line rather than a venture-backed growth equity story.

Valitacell firmographics

Firmographics
Name
Valitacell
Legal name
ValitaCell Ltd
Website
https://valitacell.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
ValitaCell is a Dublin-based biotechnology company that develops fluorescence polarization-based IgG quantification assays (Valita Titer) for rapid biologics drug development, sold exclusively through parent Beckman Coulter Life Sciences.
Ownership category
akta.pro rank

Valitacell industry classification

Industry
Product category
Biologics Analytics Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAIAA
High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAALAB
Immunoassay Diagnostics (ELISA, chemiluminescence, serology)

Keywords

  • Biologics analytics reagents
  • IgG quantification assays
  • Fluorescence polarization assays
  • Monoclonal antibody screening
  • Protein aggregation testing

Where Valitacell is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Markets served

Valitacell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Revenue model

  1. Assay Kit Sales: Sale of Valita Titer IgG quantification assay kits in 96-well and 384-well plate formats. Products include VAL003 (2.5-100 mg/L, 96-well at $6,782), VAL004 (100-2000 mg/L, 96-well at $8,975), VAL013 (2.5-100 mg/L, 384-well at $27,128), and VAL014 (100-2000 mg/L, 384-well).

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goValita Titer IgG Quantification Assay 96-well (2.5 - 100 mg/L) - VAL003
Unit PricingPay-as-you-goValita Titer IgG Quantification Assay 96-well (100 - 2000 mg/L) - VAL004
Unit PricingPay-as-you-goValita Titer IgG Quantification Assay 384-well (2.5 - 100 mg/L) - VAL013
Unit PricingPay-as-you-goValita Titer IgG Quantification Assay 384-well (100 - 2000 mg/L) - VAL014

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Valitacell product offering

Product offering

Core offering

ValitaCell develops and sells plate-based fluorescence polarization assay kits that quantify IgG antibodies directly from cell suspension without sample preparation, delivering results in under 15 minutes for biopharmaceutical clone screening, cell line development, and process optimization workflows. Its portfolio includes Valita Titer assays in 96-well and 384-well formats across low and high IgG concentration ranges, plus Valita Aggregation Pure kits for protein aggregation measurement, distributed exclusively through Beckman Coulter Life Sciences.

Product overview

ValitaCell (a Beckman Coulter company) offers a portfolio of plate-based fluorescence polarization assays for rapid IgG quantification in biologics drug discovery and development. The core product line consists of Valita Titer Assays available in 96-well and 384-well formats, each offered in two IgG concentration ranges (2.5-100 mg/L and 100-2000 mg/L). These assays measure IgG directly in cell suspension without sample preparation, providing results in under 15 minutes. Valita Aggregation Pure Assay Kits complement the titer assays for protein aggregation measurement. The complete solution can be bundled with Agilent BioTek multimode microplate readers for integrated protein titer and aggregation measurement workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • Valita Titer: Plate-based, 96- and 384-well assays for rapid, cost-effective IgG quantification using fluorescence polarization technology. Valita Titer is among the industry's fastest IgG tests.
  • Valita Aggregation Pure

Products and services

  • Valita Titer IgG Quantification Assay 96-well (2.5 - 100 mg/L) Plate-based 96-well fluorescence polarization assay for rapid IgG quantification directly from cell suspension, covering the 2.5-100 mg/L concentration range, with results in under 15 minutes; targeted at biopharmaceutical clone screening and cell line development workflows.
  • Valita Titer IgG Quantification Assay 96-well (100 - 2000 mg/L) Plate-based 96-well fluorescence polarization assay for rapid IgG quantification directly from cell suspension, covering the 100-2000 mg/L high-titer concentration range, with results in under 15 minutes; intended for high-titer bioprocess samples.
  • Valita Titer IgG Quantification Assay 384-well (2.5 - 100 mg/L) High-throughput 384-well fluorescence polarization assay for rapid IgG quantification, covering the 2.5-100 mg/L concentration range, enabling increased throughput for clone screening during drug discovery and development.
  • Valita Titer IgG Quantification Assay 384-well (100 - 2000 mg/L) High-throughput 384-well fluorescence polarization assay for rapid IgG quantification, covering the 100-2000 mg/L high-titer concentration range, designed for high-titer samples in scaled-up clone screening workflows.
  • Valita Aggregation Pure Assay Kits Companion assay kits for protein aggregation measurement that, when bundled with Valita Titer assays and Agilent BioTek multimode microplate readers, enable a complete sub-15-minute protein titer and aggregation measurement workflow for biologics analytics.

Quantifiable outcome

  • Results in less than 15 minutes (vs hours for ELISA/HPLC)
  • +4 more outcomes

Companies that use Valitacell

Customer profile

Segments3 records

Ideal customer profiles2 records

Valitacell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Valitacell partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Beckman Coulter Life SciencescoreChannel Partner/ Reseller/ DistributorBeckman Coulter Life Sciences serves as the exclusive global distributor for ValitaCell products including Valita Titer IgG quantification assays and Valita Aggregation Pure assay kits. The products are integrated into Beckman Coulter's reagent portfolio and sold through their global sales network, e-commerce platform, and distribution channels. ValitaCell is identified as a Beckman Coulter Company, indicating a close distribution and ownership relationship.

Recent moves5 records

Expansion highlights4 records

Valitacell competitors and assessment

Company assessment

Broad incumbents

  • Bio-Rad Laboratories: Bio-Rad offers Bio-Plex and ProA-based assays for IgG quantification in biologics workflows. As a broad incumbent in life science research, it competes with ValitaCell in clone screening and titer measurement within the same biopharma customer base.
  • Cytiva: Cytiva supplies Protein A affinity columns and related titer measurement workflows for mAb manufacturing. It operates as a broad bioprocess incumbent whose analytics and consumables overlap with ValitaCell's cell line development focus.
  • Thermo Fisher Scientific: Thermo Fisher offers ELISA kits, Protein A binding assays, and automated platforms for IgG titer across its life sciences portfolio. As a broad incumbent, it competes for the same biopharma analytics budgets ValitaCell targets via Beckman Coulter.
  • Merck KGaA / MilliporeSigma: MilliporeSigma supplies ELISA-based titer assays and Prozain A / Protein A affinity products for clone screening in mAb development. As a broad life science tools incumbent, it competes for the same IgG quantification dollars.

Direct peers

  • Repligen: Repligen sells the CTG (Cell Titer-Glo) and Protein A titer measurement systems used in bioprocess development. It directly competes with Valita Titer for rapid IgG quantification in cell line development, and is a similarly specialized life science tools provider for biologics.
  • Sartorius (ForteBio): ForteBio (now part of Sartorius) markets Octet BLI-based biosensors for rapid, label-free protein quantification including IgG titer. It targets the same clone screening and bioprocess development use cases as ValitaCell and is the most cited direct competitor on speed/throughput.
  • Pall Corporation (Danaher): Pall offers the Octet and other BLI-based systems (alongside other analytics) for rapid protein titer measurement; it is also a Danaher company, making it a direct intra-portfolio peer to ValitaCell with overlapping mAb workflow offerings.

Emerging players

  • Agilent Technologies: Agilent's BioTek line of multimode microplate readers is the instrument layer paired with Valita Titer assays. Agilent is adjacent/partnering rather than directly competing, but its instrumentation underpins the throughput positioning of ValitaCell's 384-well assays.
  • PerkinElmer: PerkinElmer offers AlphaLISA and other homogeneous immunoassays for rapid IgG quantification in high-throughput formats. It overlaps with ValitaCell's plate-based, no-wash assay approach and is positioned as a competing rapid titer solution.

Others

  • Yokogawa / Sysmex (Cell Line Development Tools): Providers of clone screening workstations and analytics for cell line development that integrate with rapid IgG titer assays. Included as ecosystem participants adjacent to ValitaCell's core assay workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Valitacell social profiles

Digital presence

Valitacell compliance and trust

Trust signal

Compliance1 record

Valitacell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valitacell leadership team

Management profile

Number of profiles

Profiles1 record

Valitacell funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valitacell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valitacell

What does Valitacell do?

ValitaCell develops and sells plate-based fluorescence polarization assay kits that quantify IgG antibodies directly from cell suspension without sample preparation, delivering results in under 15 minutes for biopharmaceutical clone screening, cell line development, and process optimization workflows. Its portfolio includes Valita Titer assays in 96-well and 384-well formats across low and high IgG concentration ranges, plus Valita Aggregation Pure kits for protein aggregation measurement, distributed exclusively through Beckman Coulter Life Sciences.

Is Valitacell a public or private company?

Valitacell is a private company. It is classified as corporate owned and is currently operating.

When was Valitacell founded?

Valitacell was founded in 2014. It employs 1 to 10 people.

Where is Valitacell based?

Valitacell is headquartered in Dublin, Ireland, in the Europe region.

How does Valitacell make money?

One revenue line is on record: assay Kit Sales.

Who are Valitacell's main competitors?

Broad incumbents on record are Bio-Rad Laboratories, Cytiva, Thermo Fisher Scientific and Merck KGaA / MilliporeSigma. Direct peers are Repligen, Sartorius (ForteBio) and Pall Corporation (Danaher). Emerging players are Agilent Technologies and PerkinElmer. Yokogawa / Sysmex (Cell Line Development Tools) is listed as an others.

Does Valitacell have an API?

No public API is recorded for Valitacell.

What industry is Valitacell in?

Valitacell's product category is Biologics Analytics Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAIAA, High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Think BusinessIrish biotech firm ValitaCell acquired by US player | ThinkBusinessBeckman Coulter Life Sciences acquired Irish biotech ValitaCell for an undisclosed sum, with its Dublin and Galway locations remaining operational. ValitaCell develops analytical technologies for biopharmaceuticals, including the ValitaTiter assay, and aims to reduce cost and time to market for new therapeutics.SolentimNova BiomedicalNova Biomedical delivers analytical instruments and services for bioprocessing, clinical, veterinary, and food & beverage industries. The company emphasizes innovation, quality, and performance, and offers service and support to ensure productivity.PR NewswireAndrew Alliance SA et Valitacell Ltd collaborent pour automatiser les aspects critiques du développement de lignées cellulairesAndrew Alliance S.A., a Geneva-based robotics company, and Valitacell Ltd., an Ireland-based biotechnology company, announced a collaboration agreement on February 5, 2019, to integrate Valitacell's cell line development applications into Andrew Alliance's cloud-based OneLab software platform. The partnership aims to transform biological drug manufacturing by combining Valitacell's intelligent analytical technologies with Andrew Alliance's connected devices to simplify biomanufacturing processes, improve production productivity, accelerate time-to-market, and reduce overall product costs. Both companies described the collaboration as a breakthrough solution to address challenges facing the biopharmaceutical industry.PR NewswireAndrew Alliance SA y Valitacell Ltd colaboran en el desarrollo de la línea celularAndrew Alliance SA and Valitacell Ltd announced a collaboration to integrate Valitacell's cell line development applications into Andrew Alliance's OneLab cloud-based software platform. This partnership aims to automate critical aspects of biopharmaceutical manufacturing by combining Valitacell's intelligent analytics with Andrew Alliance's connected robotic devices to improve productivity and reduce costs.PR NewswireAndrew Alliance SA und Valitacell Ltd wollen gemeinsam kritische Aspekte der Zelllinienentwicklung automatisierenAndrew Alliance S.A., a robotics manufacturer based in Geneva, and Valitacell Ltd., an Irish biotechnology company, announced a cooperation agreement on February 5, 2019 to integrate Valitacell's cell line development applications into Andrew Alliance's cloud-based OneLab software platform. The partnership combines Valitacell's analytical technologies with Andrew Alliance's networked laboratory devices to streamline biopharmaceutical manufacturing processes, accelerate time to market, and reduce product costs for biological drugs used in precision medicine.PR NewswireAndrew Alliance SA and Valitacell Ltd Collaborate to Automate Critical Aspects of Cell Line DevelopmentAndrew Alliance SA and Valitacell Ltd announced a collaboration to integrate Valitacell's cell line development applications into Andrew Alliance's cloud-based software solution, OneLab. This partnership combines Valitacell's analytical technologies with Andrew Alliance's connected devices to streamline biomanufacturing processes. The initiative aims to improve manufacturing productivity, accelerate time to market for biologic drugs, and reduce overall costs.